Lv31
376 积分 2023-07-05 加入
Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer
3小时前
已关闭
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
3小时前
已完结
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
12天前
已完结
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
20天前
已完结
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
1个月前
已完结
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
1个月前
已完结
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
1个月前
已完结
Safety and effectiveness of tunneled peripherally inserted central catheters versus conventional PICC in adult cancer patients
2个月前
已完结
Using recombinant human thyroid‐stimulating hormone for the diagnosis of recurrent thyroid cancer
4个月前
已完结
Recombinant human TSH versus hypo thyroidism
4个月前
已关闭
皖公网安备34019202002308
